Richard Greil, Prof. MD, 

CEO CCCIT non-profit GmbH

r.greil@salk.at

Michaela Schachner, MSc

Central Trial Coordinator

m.schachner@salk.at

www.cccit.at

CCIT has more than 10 years of expertise in organizing and conducting clinical trials

During the past 10 years the number of patients enrolled in CCCIT studies increased from about 1600 in 2003 to about 10.000 patients in 2017. In total, CCCIT has coordinated and conducted about 600 clinical trials. 

CCCIT coordinates and conducts all clinical trials at the 3rd Medical Department of the Paracelsus Medical University Salzburg. The best and earliest access for the newest drug-based tumor therapy is granted. The CCCIT has been established as an international accepted center for clinical trials with about 6400 patients participating.

 

The main focus of the CCCIT is to guarantee that patients can access as soon as possible the latest and most innovative cancer therapies from the top field of research. Because of this, patients can get individualized therapies specifically fitted for their unique disease situation, which often will not be available on the market for years.

 

CCCIT is focusing on “Phase I Trials” to give patients another therapy option when all other possible ways are exhausted. Participation is strictly voluntary and only after thorough information by trained physicians and sufficient time for consideration.

Patients in “Phase I Trials” are closely monitored to ensure their safety and well-being. 

 

More about CCCIT

Center for Clinical Cancer and Immunology Trials (CCCIT)

Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at

Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at